Skip to main content
OpenTrials
Completed

NCT Number: NCT01605435

Ghrelin Dose Finding In Frail Elderly

Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The purpose of this study is to determine the optimal subcutaneous ghrelin dose as a potential intervention for frail elderly individuals. We will examine food intake and metabolic parameters after placebo and ghrelin administration at three escalating subcutaneously administered doses.

Completed

Looking for future studies?

Notify Me

Key information

Age range

70 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Clinical and Translational Research Center, University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

This study is to determine the optimal ghrelin dose for use in a daily subcutaneous dosing study in frail individuals. Using data from our previous study and the published literature, we have designed a single blind, single dose administration study in which we will examine food intake after ghrelin administration and metabolic parameters (plasma glucose, insulin, free fatty acids, and cortisol) pre and post ghrelin administration.We have selected a dose range using our own and previously published studies from which we will determine subcutaneous doses to use in subsequent studies. The selection criteria for subsequent studies will be the dose that maximizes food intake by more than 30% without inducing hyperglycemia or raising cortisol levels. Participants must meet all inclusion criteria and have no exclusion criteria. Data will be analyzed after the first three participants have completed the protocol and used to inform dose modifications for the next three participants. Data from this portion of the study will be analyzed immediately after its completion, to allow updates to the design of the next study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • We will include men and women aged 70 or older who are able to provide informed consent and are frail by the Fried criteria (Table 1).
  • Table 1. Frailty criteria. Individuals with three, four, or all five criteria are frail.
  • Weight loss: Unintentional weight loss of >5% over the previous year

Exhaustion: Two statements are read:

  • I felt that everything I did was an effort
  • I could not get going. The question is asked "How often in the last week did you feel this way?" 0 = rarely or none of the time (<1 day), 1 = some or a little of the time (1-2 days), 2 = a moderate amount of the time (3-4 days), or 3 = most of the time. A "2" or "3" response to either question is a positive response.
  • Low physical activity: Kcal/week of physical activity calculated from the short version of the Minnesota Leisure Time Activity questionnaire.40 < 383 kcals in men or < 270 kcals/wk in women is positive for this criterion.
  • Slow walking speed: A usual pace, 15-ft walk timed from a defined standing start. For men ≤173 cm tall and women ≤159 cm, ≥7 sec, and for men >173 cm and women > 159 cm, ≥ 6 sec is positive for this criterion.
  • Weakness: Hand grip strength measured with a dynamometer. The average of three measurements performed in the dominant hand is used. For men with BMI ≤ 24 kg/m2, the cutoff is ≤ 29 kg, for BMI 24.1 to 26 the cutoff is ≤ 30 kg, for BMI 26.1 to 28 the cutoff is ≤30 kg, and for BMI > 28 the cutoff is ≤ 32 kg. For women with BMI ≤ 23 kg/m2, the cutoff is ≤ 17 kg, for BMI 23.1 to 26 the cutoff is ≤ 17.3 kg, for BMI 26.1 to 29 the cutoff is ≤ 18 kg, and for BMI > 29 the cutoff is ≤ 21 kg for a positive criterion.

Exclusion criteria

  • Diabetes mellitus or fasting glucose ≥ 126 mg/dL
  • Hospitalization for stroke, myocardial infarction, coronary artery bypass graft surgery, vascular surgery in the past six months.
  • NYHA Class III or IV congestive heart failure
  • Therapy for cancer in the past 12 months, except non-melanoma skin cancer
  • BMI≥ 30 kg/m2
  • Current use of corticosteroids other than topical, ophthalmic, and inhaled preparations
  • Therapy with megestrol acetate or dronabinol within the last 6 weeks
  • TSH measured as <0.4 mU/L or greater than 10mU/L
  • Abnormal liver function tests (LFTs > 2x upper limit of normal)
  • Hemoglobin < 11g/dL
  • Insulin-like growth factor-I (IGF-I) above the age-specific reference range
  • History of surgery within the last 30 days
  • Unstable medical or psychological conditions or unstable home or food environment
  • Cognitive deficit as defined by a Folstein Mini Mental State Exam score < 18/30
  • Depression (defined as a score of >11 on the Geriatric Depression Questionnaire)

-

Treatment and study plan

Ghrelin Group 1

Drug

The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.

Other names: First dose escalation group

Ghrelin Group 2

Drug

The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.

Other names: Second dose escalation group

Primary outcomes

  1. Treatment Emergent Adverse Events

    Time frame: 30 days following the last administration of study treatment.

    Number and type of treatment emergent adverse events

  2. Median Energy Intake

    Time frame: 30 mins post-ghrelin or placebo

    Median energy intake at breakfast, which was served 30 minutes post-placebo or ghrelin administration demonstrated at each dose level.

  3. Percentage of Total Energy Intake Relative to Placebo

    Time frame: 30 mins post-ghrelin or placebo

    % of total energy relative to placebo - breakfast served 30 minutes post-placebo or ghrelin administration.

  4. Growth Hormone

    Time frame: 30 minutes after ghrelin administration

    median growth hormone peak 30 minutes after placebo/ghrelin.

  5. Cortisol Level

    Time frame: 0, 60 and 120 minutes after dosing

    Cortisol response to ghrelin or placebo - levels at 0, 60 and 120 minutes after dosing

  6. Glucose Levels

    Time frame: 0 minutes (baseline) and 60 or 90 minutes from dosing

    Median fasting and peak postprandial Glucose levels (60 or 90 minutes from dosing) at placebo and at each ghrelin dose.

  7. Insulin Level

    Time frame: 0 and 90 minutes after dosing

    Median fasting insulin levels at baseline and 90 minutes after dosing

  8. Free Fatty Acid Level

    Time frame: 90 and 120 minutes after dosing

    Free Fatty Acid levels (mEq/L) at 60 and 90 minutes after meal (90 and 120 minutes)

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

Ghrelin In Frail Elderly Subcutaneous Dose Finding Study

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
May 24, 2012
Registry last updated
Dec 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.